Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2012 | Research

Enforced effect of tk-MCP-1 fusion gene in ovarian cancer

Authors: Shuhui Hong, Ping Zhang, Hui Zhang, Lin Jia, Xun Qu, Qifeng Yang, Fengnian Rong, Beihua Kong

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Abstract

Objective

The efficiency of HSV-tk/GCV system is not high because of insufficient gene transfer and incompletely initiative of host antineoplastic potency. The present study was designed to assess the antitumor efficacy of tk-MCP-1 on ovarian cancer in vitro and vivo.

Methods

A novel bicistronic expression system can help to improve the expression level of a gene in a stable manner. pLXSN/tk-MCP-1 co-expressing tk and MCP-1 genes was constructed using a pLXSN retroviral vector and an internal ribosome entry site sequence by restriction enzyme. Western blot was performed to determine tk and MCP-1 expression in the infected SKOV₃. The GCV-sensitively tumoricidal activities of SKOV₃/tk-MCP-1 with or without monocytes were compared to those of SKOV₃ expressing HSV-tk or MCP-1. We investigated the growth of subcutaneous tumors in SCID mice immuno-reconstituted, and evaluated the antitumor effect of MCP-1 in conjunction with suicide gene.

Results

The significant GCV-sensitively tumoricidal activity of pLXSN/tk-MCP-1 was observed when compared with those of pLXSN/tk, pLXSN/MCP-1 and pLXSN/neo, especially when monocytes were added. The growth of subcutaneous tumors in SCID mice immuno-reconstituted was markedly suppressed by co-delivery of HSV-tk and MCP-1 genes, and the enhanced antitumor effect was associated with the recruitment of monocytes.

Conclusion

These results demonstrated pLXSN/tk-MCP-1 presented an enhanced antitumor effects on ovarian cancer by orchestration of immune responses.

Available only for authorised users

Seibaek L, Petersen LK, Blaakaer J, Hounsgaard L: Symptom interpretation and health care seeking in ovarian cancer. BMC Womens Health. 2011, 11: 31-10.1186/1472-6874-11-31.PubMedCentralCrossRefPubMed

Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, et al: ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. PLoS Biol. 2011, 9: e1001156-10.1371/journal.pbio.1001156.PubMedCentralCrossRefPubMed

Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003, 3: 502-516. 10.1038/nrc1123.CrossRefPubMed

Huber BE, Richards CA, Austin EA: Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann N Y Acad Sci. 1994, 716: 104-14. 10.1111/j.1749-6632.1994.tb21706.x. discussion 40–43CrossRefPubMed

Marais R, Spooner RA, Light Y, Martin J, Springer CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996, 56: 4735-4742.PubMed

Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL, Huang CJ, et al: Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit. 2009, 15: BR13-BR20.PubMed

Finocchiaro LM, Riveros MD, Glikin GC: Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Vet Rec. 2009, 164: 278-279. 10.1136/vr.164.9.278.CrossRefPubMed

Xu B, Liu ZZ, Zhang J, Zong XL, Cai JL: Effects of recombinant adenovirus-mediated double suicide genes on implanted human keloid: experiment with athymic mice. Zhonghua yi xue za zhi. 2008, 88: 3428-3431.PubMed

Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al: Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996, 3: 85-92.PubMed

10.

Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, et al: A “distant” bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 1997, 8: 1807-1814. 10.1089/hum.1997.8.15-1807.CrossRefPubMed

11.

Yoshimura T, Leonard EJ: Human monocyte chemoattractant protein-1: structure and function. Cytokines. 1992, 4: 131-152.PubMed

12.

Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994, 91: 3652-3656. 10.1073/pnas.91.9.3652.PubMedCentralCrossRefPubMed

13.

Tsuchiyama T, Nakamoto Y, Sakai Y, Mukaida N, Kaneko S: Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci. 2008, 99: 2075-2082. 10.1111/j.1349-7006.2008.00951.x.CrossRefPubMed

14.

Iida N, Nakamoto Y, Baba T, Kakinoki K, Li YY, Wu Y, et al: Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. J Leukoc Biol. 2008, 84: 1001-1010. 10.1189/jlb.1107791.CrossRefPubMed

15.

Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, Murakami K, et al: Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Anticancer Res. 2007, 27: 2305-2310.PubMed

16.

Faneca H, Cabrita AS, Simoes S: Pedroso de Lima MC. Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Biochim Biophys Acta. 2007, 1768: 1093-1102. 10.1016/j.bbamem.2006.12.017.CrossRefPubMed

17.

Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, et al: Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000, 7: 1086-1099. 10.1038/sj.cgt.7700215.CrossRefPubMed

18.

Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, Zhang Y, et al: Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther J Am Soc Gene Ther. 2011, 19: 1353-1359. 10.1038/mt.2011.89.CrossRef

19.

Tsuchiyama T, Kaneko S, Nakamoto Y, Sakai Y, Honda M, Mukaida N, et al: Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther. 2003, 10: 260-269. 10.1038/sj.cgt.7700571.CrossRefPubMed

20.

Nowrouzi A, Glimm H, von Kalle C, Schmidt M: Retroviral vectors: post entry events and genomic alterations. Viruses. 2011, 3: 429-455. 10.3390/v3050429.PubMedCentralCrossRefPubMed

21.

Zhang Z, Huang Y, Newman K, Gu J, Zhang X, Wu H, et al: Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Clin Cancer Res. 2009, 15: 5154-5160. 10.1158/1078-0432.CCR-09-0025.CrossRefPubMed

22.

Jiang Y, Beller DI, Frendl G, Graves DT: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol. 1992, 148: 2423-2428.PubMed

23.

Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990, 75: 1037-1050.PubMed

24.

Fidler IJ: Macrophage therapy of cancer metastasis. CIBA Found Symp. 1988, 141: 211-222.PubMed

25.

Yamashiro S, Takeya M, Nishi T, Kuratsu J, Yoshimura T, Ushio Y, et al: Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol. 1994, 145: 856-867.PubMedCentralPubMed

26.

Ramesh R, Munshi A, Marrogi AJ, Freeman SM: Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int J Cancer. 1999, 80: 380-6. 10.1002/(SICI)1097-0215(19990129)80:3<380::AID-IJC8>3.0.CO;2-G.CrossRefPubMed

27.

Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ: The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. 1995, 92: 167-174. 10.1016/0304-3835(95)03771-N.CrossRefPubMed

28.

Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, et al: Prodrug-activated gene therapy: involvement of an immunological component in the “bystander effect”. Cancer Gene Ther. 1996, 3: 83-88.PubMed

29.

Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, et al: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996, 56: 3758-3762.PubMed

30.

Yamaguchi A, Goi T, Seki K, Ohtaki N, Maehara M, Kobayashi T, et al: Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Oncology. 1998, 55: 400-403. 10.1159/000011885.CrossRefPubMed

31.

Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, et al: Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res. 1998, 89: 1033-1040. 10.1111/j.1349-7006.1998.tb00493.x.CrossRefPubMed

32.

Freeman SM, Ramesh R, Marrogi AJ: Immune system in suicide-gene therapy. Lancet. 1997, 349: 2-3. 10.1016/S0140-6736(97)22001-5.CrossRefPubMed

Title: Enforced effect of tk-MCP-1 fusion gene in ovarian cancer
Authors: Shuhui Hong
Ping Zhang
Hui Zhang
Lin Jia
Xun Qu
Qifeng Yang
Fengnian Rong
Beihua Kong
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-31-74

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables

Decreased expression of LATS1 is correlated with the progression and prognosis of glioma

Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma

Circulating microRNAs in cancer: origin, function and application

An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma

Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-κB

Keynote webinar | Spotlight on antibody–drug conjugates in cancer